Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares Issued
Ratios

Ligand Pharmaceuticals (LGNDZ) Receivables Refunds (2018 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Receivables Refunds for 9 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • Quarterly Receivables Refunds fell 64.5% to $1.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Dec 2025, down 64.5% year-over-year, with the annual reading at $1.4 million for FY2025, 64.5% down from the prior year.
  • Receivables Refunds hit $1.4 million in Q4 2025 for Ligand Pharmaceuticals, up from $536000.0 in the prior quarter.
  • In the past five years, Receivables Refunds ranged from a high of $7.8 million in Q3 2024 to a low of $536000.0 in Q3 2025.
  • Historically, Receivables Refunds has averaged $3.6 million across 5 years, with a median of $4.2 million in 2024.
  • Biggest five-year swings in Receivables Refunds: skyrocketed 179.34% in 2021 and later plummeted 93.14% in 2025.
  • Year by year, Receivables Refunds stood at $6.2 million in 2021, then fell by 25.5% to $4.6 million in 2022, then skyrocketed by 38.6% to $6.4 million in 2023, then plummeted by 36.31% to $4.1 million in 2024, then plummeted by 64.5% to $1.4 million in 2025.
  • Business Quant data shows Receivables Refunds for LGNDZ at $1.4 million in Q4 2025, $536000.0 in Q3 2025, and $828000.0 in Q2 2025.